[Treatment of chronic active hepatitis (HBsAg +,HBeAg +) with isoprinosine. Clinical evaluation].
Cianciara
J
J
Loch
T
T
Babiuch
L
L
Dabrowska-Bernstein
B
B
Stasiak
A
A
Dabrowski
M
M
Pawińska
A
A
D000328:Adult; D002986:Clinical Trials as Topic; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D006521:Hepatitis, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008875:Middle Aged
D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007288:Inosine; D007542:Inosine Pranobex
Leczenie przewlekłego aktywnego zapalenia watroby (HBsAg +, HBeAg +) izoprynozyna. Ocena kliniczna.